

Electronic Supplementary Material (ESI) for RSC advances.

**Study of novel pyrazolo[3,4-d]pyrimidine derivatives as selective
TgCDPK1 inhibitors: molecular docking, structure-based 3D-QSAR
and molecular dynamics simulation**

Shaojie Ma,^{ab} Shengfu Zhou,^a Weicong Lin,^a Rong Zhang,^a Wenjuan Wu,^{a*} and Kangcheng Zheng^c

^a: Department of Physical Chemistry, College of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China. E-mail: wuwenjuan83@126.com; Tel: +86 2039352119

^b: Department of Pharmacy, Kangda College of Nanjing Medical University, Lianyungang 222000, China






^c: School of Chemistry and Chemical Engineering, Sun Yat-Sen University, Guangzhou 510275, China







Electronic Supplementary Information









Table of Contents

Supplementary tables (Table S1-S2)	S2-S7
Supplementary figure (Figures S1-S3)	S8-S10

Table S1 Structures and experimental values IC₅₀ (μM) of pyrazolo[3,4-d]pyrimidine derivatives

NO.	R ₁	R ₂	TgCDPK1		Src		Distance (APD=2.455)	
			IC ₅₀	pIC ₅₀	IC ₅₀	pIC ₅₀		
1	2b		-C(CH ₃) ₃	0.0045	8.3468	0.13	6.8861	-
2*	3a		-CH(CH ₃) ₂	0.019	7.7212	1.3	5.8861	1.404
3*	3b	3	b	0.0073	8.1367	0.58	6.2366	1.813
4	4a		a	0.04	7.3979	5.1	5.2924	-
5	5a		a	0.005	8.3010	0.65	6.1871	-
6	5b	5	b	0.0041	8.3872	0.18	6.7447	-
7	6a		a	0.012	7.9208	1.5	5.8239	-

8	7a		a	0.0091	8.0410	1.2	5.9208	-
9	8a		a	0.0036	8.4437	0.29	6.5376	-
10*	8b	8	b	0.013	7.8861	0.52	6.2840	1.855
11	9b		b	0.0025	8.6021	2.1	5.6778	-
12*	10a		a	0.13	6.8861	8.8	5.0555	1.798
13	10b	10	b	0.031	7.5086	2.2	5.6576	-
14*	11a		a	0.005	8.3010	0.065	7.1871	1.578
15	11b	11	b	0.0079	8.1024	0.12	6.9208	-
16	12a		a	0.024	7.6198	0.2	6.6990	-

17*	13b		b	0.0031	8.5086	4.1	5.3872	1.539
18	14a		a	0.006	8.2218	0.67	6.1739	-
19	14b	14	b	0.02	7.6990	2	5.6990	-
20	15a		a	0.005	8.3010	0.38	6.4202	-
21	15b	15	b	0.033	7.4815	2.2	5.6576	-
22	17a		a	0.01	8.0000	0.55	6.2596	-
23	18a		a	0.0006	9.2218	0.2	6.6990	-
24	19a		a	0.0032	8.4949	0.3	6.5229	-
25	20a		a	0.0054	8.2676	0.26	6.5850	-
26	20b	20	b	0.2	6.6990	1.1	5.9586	-
27*	21a		a	0.0009	9.0458	0.78	6.1079	1.445

28*	22a		a	0.0008	9.0969	0.041	7.3872	1.388	
29	22n	22			0.0023	8.6383	3.1	5.5086	-
30	23a		a	0.011	7.9586	0.28	6.5528	-	
31	23n	23	n	0.0013	8.8861	1.8	5.7447	-	
32	24a		a	0.0055	8.2596	0.28	6.5528	-	
33	24n	24	n	0.0007	9.1549	0.38	6.4202	-	
34*	25a		a	0.004	8.3979	0.27	6.5686	1.210	
35	25n	25	n	0.0007	9.1549	1.6	5.7959	-	
36	15g			0.0026	8.5850	5	5.3010	-	
37	15h	15		0.0024	8.6198	5.6	5.2518	-	
38	15i	15		0.0034	8.4685	8.7	5.0605	-	
39*	15k	15		0.0043	8.3665	0.73	6.1367	1.612	
40	15l	15		0.0061	8.2147	1.6	5.7959	-	

41*	15m	15		0.0028	8.5528	0.81	6.0915	1.254
42	15s	15		0.0019	8.7212	3.3	5.4815	-
43	15t	15		0.0022	8.6576	5.2	5.2840	-
44*	15u	15		0.0027	8.5686	6.3	5.2007	1.380
45	15v	15		0.003	8.5229	6.7	5.1739	-
46	15w	15		0.0043	8.3665	8.2	5.0862	-

*Compounds in the test set

Table S2 Structure and predicted activities of new designed compounds

No.	R ₁	R ₂	Predicted pIC ₅₀		Distance (APD=2.455)
			TgCDPK1	Src	
D1			9.4164	3.9511	0.799
D2			9.3971	3.8977	0.867
D3			9.3524	4.1102	0.798
D4			9.3514	3.8793	1.095
D5			9.3381	4.8057	0.781
D6			9.3226	3.8583	1.608




Fig.S1. (a) and (b), the alignment of the 34 studied compounds for TgCDPK1 and Src series.




Fig.S2. Superimposition of the average structure from the last 2 ns of the MD simulation (magenta) and the initial structure (yellow). (a) 3SXF-23 complex, (b) 3SXF-4 complex, (c) 3UQF-23 complex, (d) 3UQF-4 complex.




Fig.S3. The interaction of inhibitors with water molecules in **23-3SXF**(a) and **23-3UQF**(b) systems.